Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (191-200 of 272) with videos related to

Pageof 28
Sort By:
Kidney International|March 29, 2026
Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouseJingyi Wu, Tong Xie, Zhao Zhang, et al.
Kidney International Reports|October 26, 2020
IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK BiobankKittiya Sukcharoen, Seth A Sharp, Nicholas J Thomas, et al.
Kidney International|June 7, 2025
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathyLaura Kooienga, Jeannette Lo, Eun Young Lee, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International Reports|April 30, 2025
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsSean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 25, 2020
Macrophage interactions with collecting duct epithelial cells are capable of driving tubulointerstitial inflammation and fibrosis in immunoglobulin A nephropathyIzabella Z A Pawluczyk, Maria S F Soares, William A Barratt, et al.
Kidney International|May 29, 2020
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction ToolSean J Barbour, Mark Canney, Rosanna Coppo, et al.
Kidney International|November 26, 2023
Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trialDavid Wimbury, Masahiro Muto, Jasraj S Bhachu, et al.
Journal of the American Society of Nephrology : JASN|February 18, 2017
Galactosylation of IgA1 Is Associated with Common Variation in <i>C1GALT1</i>Daniel P Gale, Karen Molyneux, David Wimbury, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled TrialJonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
Pageof 28

Showing results (191-200 of 272) with videos related to

Sort By:
Pageof 28
Kidney International|March 29, 2026
Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouseJingyi Wu, Tong Xie, Zhao Zhang, et al.
Kidney International Reports|October 26, 2020
IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK BiobankKittiya Sukcharoen, Seth A Sharp, Nicholas J Thomas, et al.
Kidney International|June 7, 2025
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathyLaura Kooienga, Jeannette Lo, Eun Young Lee, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International Reports|April 30, 2025
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsSean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 25, 2020
Macrophage interactions with collecting duct epithelial cells are capable of driving tubulointerstitial inflammation and fibrosis in immunoglobulin A nephropathyIzabella Z A Pawluczyk, Maria S F Soares, William A Barratt, et al.
Kidney International|May 29, 2020
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction ToolSean J Barbour, Mark Canney, Rosanna Coppo, et al.
Kidney International|November 26, 2023
Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trialDavid Wimbury, Masahiro Muto, Jasraj S Bhachu, et al.
Journal of the American Society of Nephrology : JASN|February 18, 2017
Galactosylation of IgA1 Is Associated with Common Variation in <i>C1GALT1</i>Daniel P Gale, Karen Molyneux, David Wimbury, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled TrialJonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
Pageof 28